In the days before the technique was developed, treatment for Parkinson’s disease meant ... in harmony with complex human needs and the natural environment. Since then, the foundation has ...

The King's College London researchers say the discovery could lead to new screening tools and treatments. Experts said larger studies and more affordable scans were needed first. Parkinson's is a ...

Figure 3: Effect of intraintestinal levodopa infusion on motor complications in Parkinson's disease. On the basis of these findings, we hypothesized that an oral levodopa treatment strategy that ...

Why this matters for the future of Parkinson’s treatment While we’re not saying ... this discovery adds to our growing understanding of how natural compounds might help prevent neurological ...

Considering taking supplements to treat parkinson disease? Below is a list of common natural remedies used to treat or reduce the symptoms of parkinson disease. Follow the links to read common ...

A literature review of the potential clinical and socioeconomic impact of targeting unmet needs in Parkinson’s disease. Parkinson’s disease (PD ... the growing socioeconomic burden of the disease and ...

By taking cells "back in time", the researchers hope their findings could aid the search for new treatments. "The journey of Parkinson's, we think, is quite a long one," said Dr Dayne Beccano ...

Rates of Parkinson’s disease are rising for reasons which remain unclear, yet it remains an incurable illness. Right now, the main treatment available to patients is levodopa, a therapy which ...

Find out about the causes, symptoms and treatments. Parkinson’s disease is a brain disease that affects around 145,000 ... During the first few years of having Parkinson’s, problems with movement can ...

In a significant advancement for Parkinson's disease (PD) treatment, NeuroDerm Ltd., a subsidiary of Mitsubishi Tanabe Pharma Corporation, has unveiled the results of the Phase 3 BouNDless trial ...

Clinical studies have revealed that rasagiline is associated with improved outcomes in patients with early Parkinson's disease ... patients may be more prone to treatment-emergent adverse ...

Belgian pharmaceutical company UCB is dropping its development of minzasolmin in patients with Parkinson's' disease after the ORCHESTRA study failed to meet its primary and secondary endpoints.